预约演示

Emergent secures $704m contract for Ebola treatment Ebanga

2023-08-01

交易

疫苗

Phalguni Deswal

@Phalguni_GD

The contract is divided into two option periods, one advanced development option worth $121m, and the second procurement option valued at $583m over a five-year period. Image Credit: Belen B Massieu / Shutterstock.

Emergent BioSolutions has won a ten-year contract worth up to $704m to develop Ebanga (ansuvimab-zykl), a treatment approved by the US Food and Drug Administration (FDA) for the Ebola virus disease (EVD).

The contract has been given by the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS).

Emergent BioSolutions Ebanga ansuvimab-zykl Food and Drug Administration (FDA)Ebola virus disease (EVD)

ReportsLOA and PTSR Model - MalariaBiomedical Advanced Research and Development Authority (BARDA)

ReportsLOA and PTSR Model - AT-752 in Dengue Fever GlobalData

View allCompanies IntelligenceEmergent BioSolutions IncHH&S LtdEmergent Inc.The U.S. governmentDepartment of HealthView all

Following the news, EmergentMalariae price increased by 14.6Malariaarket on 1 August, compared to the market close on the previous day. Emergent’s market cap is $392.99m.

Under the deal, Emergent will be responsible for the advanced development, manufacturing scale-up, and procurement of Ebanga, a monoclonal antibody.

Emergent has other prior relAT-752hipsDengue Fever Government.

In January 2023, the company was awarded a $379.6m contract by the US Department of Defense for the procuremeHealthViewactive skin decontamination lotion kit, Supply RSDL, for the removal of the chemical warfare agent from the skin.

The ten-year contracEmergentided into two option periods, comprising one advanced development option valued at $121m, and the second proEmergent option valued at $583m over a five-year period.

The advanced devEmergent activities consist of the post-licence development of Ebanga, including technology transfer aEbanga of scaling up manufacturing, submission of a supplemental biologics licence application to the FDA, and completion of stability studies.

Emergent023, Emergent sold its travel vaccine poUS Governmenth included vaccines for typhoid fever, cholera, and Chikungunya virus to Bavarian Nordic. Infectious diseases are a growing market, with GlobalData forecasting $150bn in global annual sales in 2029.

GlobalData is the parent company of Pharmaceutical Technology.US Department of Defense

In the press release, Emergent senior VP Paul Williams said: “Emergent is proud to continue providing solutions to and partnering with the [US] government to strengthen the medical countermeasure infrastructure that enables the development, manufacture, and delivery of essential treatments for deadly diseases.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构